Key facts
- It has raised $1.3M; the latest was Early Stage VC in Apr 2025.
- Notable investors include Innovation Authority, Edge Medical Ventures, MEDX Xelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for LifeCord
- ·The full record, as it builds
Funding rounds
No funding rounds for LifeCord are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LifeCord
Developer of transfemoral mitral chordal repair systems intended to address the challenges in the cardiovascular field. The company's system preserves the leaflet without puncturing and offers a minimally invasive transfemoral alternative to open-heart surgery, enabling healthcare professionals to provide safer and more efficient treatment options.
- Sector
- Healthcare
- HQ
- Or Yehuda, Israel
- Founded
- 2023
- Employees
- 4
- Website
- life-cord.com/
- Ownership
- Privately Held (backing)
LifeCord doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LifeCord shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LifeCord in its N-PORT filings yet. We sweep new filings monthly.